From: Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
Pt. #
Pre(0w)
Post(8w)
R-M-1
12.47%
1.70%
R-G-2
10.00%
1.59%
R-K-3
1.02%
1.88%
R-H-4
4.40%
5.83%
R-N-5
4.74%
6.20%
R-L-6
2.70%
3.59%
B-S-1
3.31%
5.94%
B-H-2
4.54%
9.29%
B-L-3
3.66%
7.05%
B-Y-4
8.18%
6.08%